All In Biotech

Drug Trial Radar · NCT02130557

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

A MULTICENTER PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB VERSUS IMATINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

Last checked: Nov 20, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 536 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

536

Actual

Start

Jul 15, 2014

Primary completion

Aug 11, 2016

Study completion Apr 17, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.

Conditions

  • Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Interventions

  • BosutinibDrug

    Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.

  • ImatinibDrug

    Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial. Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Major Molecular Response (MMR) at Month 12Time frame: Month 12

Locations

189 sites in 26 countries. Site status is shown where the registry gives one.

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • Emory University Hospital

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Kaiser Permanente Hawaii

    Honolulu, Hawaii

  • Saint Alphonsus Regional Medical Center, Cancer Care Center

    Boise, Idaho

  • Saint Alphonsus Regional Medical Center

    Boise, Idaho

  • Saint Alphonsus Caldwell Cancer Care Center

    Caldwell, Idaho

  • Saint Alphonsus Medical Center Nampa

    Nampa, Idaho

  • University of Illinois Cancer Center

    Chicago, Illinois

  • John H. Stroger, Jr. Hospital of Cook County

    Chicago, Illinois

  • Indiana Blood and Marrow Transplantation

    Indianapolis, Indiana

  • PHARMACY Department Franciscan St. Francis Health ATTN:Jill Leslie, Pharm D

    Indianapolis, Indiana

  • Cancer Center of Acadiana at Lafayette General Medical Center

    Lafayette, Louisiana

  • Lafayette General Medical Center

    Lafayette, Louisiana

  • LSU Health Sciences Center-Shreveport

    Shreveport, Louisiana

  • University Health Shreveport

    Shreveport, Louisiana

  • Rcca Md Llc

    Bethesda, Maryland

  • University of Massachusetts Memorial Medical Center, ONC/Research Pharmacy

    Worcester, Massachusetts

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • St. Joseph Mercy Hospital - Inpatient Pharmacy

    Ann Arbor, Michigan

  • St. Joseph Mercy Hospital

    Ann Arbor, Michigan

  • St. Joseph Mercy-Brighton

    Brighton, Michigan

  • St. Joseph Mercy-Canton

    Canton, Michigan

  • Chelsea Community Hospital

    Chelsea, Michigan

  • St. John Hospital&Medical Center

    Detroit, Michigan

  • St. John Hospital&Medical Center-Van Elslander Cancer Center

    Grosse Pointe Woods, Michigan

  • Van Elslander Cancer Center, Pharmacy

    Grosse Pointe Woods, Michigan

  • Minnesota Oncology Hematology, PA

    Edina, Minnesota

  • Park Nicollet Frauenshuh Cancer center

    Saint Louis Park, Minnesota

  • Lakeview Hospital

    Stillwater, Minnesota

  • North Mississippi Medical Center Hematology and Oncology Clinic

    Tupelo, Mississippi

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • NYU Winthrop Hospital - Oncology / Hematology department

    Mineola, New York

  • NYU Winthrop Hospital - Pharmacy Department

    Mineola, New York

  • Beth Israel Medical Center

    New York, New York

  • University of Rochester Investigational Drug Pharmacy

    Rochester, New York

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.